An open study of tacrolimus therapy in Rasmussen encephalitis.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 15184626.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Seven patients with Rasmussen encephalitis (RE) were treated with the immunosuppressant tacrolimus and followed for a median of 22.4 months. They were compared with 12 historical untreated RE patients (median follow-up 13.9 months). The tacrolimus-treated patients had a superior outcome regarding neurologic function and progression rate of cerebral hemiatrophy but no better seizure outcome. No treated patient, but 7 of 12 control patients, became eligible for hemispherectomy. Tacrolimus did not have any major side effects.
Medical subject headings
- Encephalitis
- Immunosuppressive Agents
- Tacrolimus